Central Sleep Apnea Prevalence and Impact on Cognitive Function in Patients With Heart Failure With Reduced or Mildly Reduced Left Ventricular Ejection Fraction

Inclusion Criteria

• •1. Diagnosed with heart failure with reduced or mildly reduced left ventricular ejection fraction (LVEF \<50%) at least 3 months prior to enrollment
• •2. New York Heart Association (NYHA) functional class II-IV
• •3. Treated and optimized on heart failure guideline directed medical therapy as indicated for at least 4 weeks, including angiotensin receptor-neprilysin inhibitors (ARNI) (or angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blocker (ARB)), aldosterone receptor antagonists, beta-blockers and/or sodium glucose co-transporter 2 (SGLT-2) antagonists
• •4. Age 50 years or older
• •5. Signed Institutional Review Board (IRB) or Ethics Committee (EC) approved informed consent
• •6. In the opinion of the investigator, subject is willing and able to comply with the protocol, including the cognitive function assessment
• •1. AHI ≥ 15 events per hour and CAHI ≥ 50% of total AHI (Case group) or AHI \< 5 events per hour (Control group) based on the baseline HSAT
• •2. Per the patient and investigator, willing and able to postpone CSA treatment until completion of the study assessment visit (Visit 3)